Update Arxiv - Revision history

Wentao at 08:37, 11 January 2023

2023-01-11T08:37:16Z

Wentao at 08:35, 11 January 2023

2023-01-11T08:35:56Z

Hasan at 03:04, 10 January 2023

2023-01-10T03:04:05Z

Hasan at 10:03, 6 January 2023

2023-01-06T10:03:49Z

Wentao: Created page with "TEST"

2023-01-06T09:52:15Z

Created page with "TEST"

New page

TEST

← Older revision		Revision as of 08:37, 11 January 2023
Line 9:		Line 9:
	===R346T, R368I, and V445P===		===R346T, R368I, and V445P===
	<big>These three mutations have never been reported in the previous variants and currently show up in the XBB variant. The mutation at site 346 was previously reported in the lambda variant, but with the amino acid Lysin(R346K) instead of Threonine(R346T) as in XBB. deLemus detected the mutation activity in this site by the end of 2021, which persistently exhibits high signal ever since. For site V445, deLemus also has detected the mutation signal in this site since April 2022. The DMS study reported an escape capability of this site over mAbs COV2-2449.</big>		<big>These three mutations have never been reported in the previous variants and currently show up in the XBB variant. The mutation at site 346 was previously reported in the lambda variant, but with the amino acid Lysin(R346K) instead of Threonine(R346T) as in XBB. deLemus detected the mutation activity in this site by the end of 2021, which persistently exhibits high signal ever since. For site V445, deLemus also has detected the mutation signal in this site since April 2022. The DMS study reported an escape capability of this site over mAbs COV2-2449.</big>
−
−	~~== <big>[[Time Course]] </big> ==~~

← Older revision		Revision as of 08:35, 11 January 2023
Line 8:		Line 8:

	===R346T, R368I, and V445P===		===R346T, R368I, and V445P===
−	<big>These three mutations have never been reported in the previous variants and currently show up in the XBB variant. The mutation at site 346 was previously reported in the lambda variant, but with the amino acid Lysin(R346K) instead of Threonine(R346T) as in XBB. deLemus detected the mutation activity in this site by the end of 2021, which persistently exhibits high signal ever since. For site V445, deLemus also has detected the mutation signal in this site since April 2022. The DMS study reported an escape capability of this site over mAbs COV2-2449.<br /></big>	+	<big>These three mutations have never been reported in the previous variants and currently show up in the XBB variant. The mutation at site 346 was previously reported in the lambda variant, but with the amino acid Lysin(R346K) instead of Threonine(R346T) as in XBB. deLemus detected the mutation activity in this site by the end of 2021, which persistently exhibits high signal ever since. For site V445, deLemus also has detected the mutation signal in this site since April 2022. The DMS study reported an escape capability of this site over mAbs COV2-2449.</big>
		+
		+	== <big>[[Time Course]] </big> ==

@@ Line 5: / Line 5: @@
 ===F486V/S, K444T===
-<big>F486V mutation previously showed up in BA.4&5 lineage. This mutation also shows up in the BQ.1 lineage and exhibits polymorphism in the XBB lineage, with the mutation from Phenylalanine to Serin (F486S). This mutation facilitates the escape from class I and II mAbs and the DMS study also reveals the same immune evasive potential over COV2-2832 mAb. deLemus outlines the mutation activity in this site by March 2022. The mutation K444T is reported in BQ.1 as well. This mutation has been reported to abolish the 2X324-neutralizing activity with various amino acids. deLemus also outlined the mutation in this site by the end of 2021.<br /></big>
+<big>F486V mutation previously showed up in BA.4&5 lineage. This mutation also shows up in the BQ.1 lineage and exhibits polymorphism in the XBB lineage, with the mutation from Phenylalanine to Serin (F486S). This mutation facilitates the escape from class I and II mAbs and the DMS study also reveals the same immune evasion capability over COV2-2832 mAb. deLemus outlines the mutation activity in this site by March 2022. The mutation K444T is reported in BQ.1 as well. This mutation has been reported to abolish the 2X324-neutralizing activity with various amino acids. deLemus also outlined the mutation in this site by the end of 2021.<br /></big>
 ===R346T, R368I, and V445P===
 <big>These three mutations have never been reported in the previous variants and currently show up in the XBB variant. The mutation at site 346 was previously reported in the lambda variant, but with the amino acid Lysin(R346K) instead of Threonine(R346T) as in XBB. deLemus detected the mutation activity in this site by the end of 2021, which persistently exhibits high signal ever since. For site V445, deLemus also has detected the mutation signal in this site since April 2022. The DMS study reported an escape capability of this site over mAbs COV2-2449.<br /></big>

← Older revision		Revision as of 10:03, 6 January 2023
Line 1:		Line 1:
−	~~TEST~~	+	==Previously Confirmed Mutations ==
		+	<big>In the last 6 months, 3 omicron sublineages have been announced as Variant of Interest (VoI), which are BA.2.75, BQ.1, and XBB. These variants bring new mutable sites that are very important for the virus to improve its fitness.<br /></big>
		+	===N460K===
		+	<big>N460K mutation is first reported in B.2.75, which became prevalent by July 2022. The mutation from Asparagine(N) to Arginine(R) at site 460 can increase the hACE2-binding affinity with the background of BA.2 mutation in the deep mutational study(DMS). Moreover, this mutation also grants immune evasive capability over monoclonal antibodies(mAbs). Not only in BA.2.75, but this mutation also shows up in the subsequent VoIs (BQ.1 and XBB). deLemus already outlined this mutation by February 2022, much earlier before it became prevalent.<br /></big>
		+
		+	===F486V/S, K444T===
		+	<big>F486V mutation previously showed up in BA.4&5 lineage. This mutation also shows up in the BQ.1 lineage and exhibits polymorphism in the XBB lineage, with the mutation from Phenylalanine to Serin (F486S). This mutation facilitates the escape from class I and II mAbs and the DMS study also reveals the same immune evasive potential over COV2-2832 mAb. deLemus outlines the mutation activity in this site by March 2022. The mutation K444T is reported in BQ.1 as well. This mutation has been reported to abolish the 2X324-neutralizing activity with various amino acids. deLemus also outlined the mutation in this site by the end of 2021.<br /></big>
		+
		+	===R346T, R368I, and V445P===
		+	<big>These three mutations have never been reported in the previous variants and currently show up in the XBB variant. The mutation at site 346 was previously reported in the lambda variant, but with the amino acid Lysin(R346K) instead of Threonine(R346T) as in XBB. deLemus detected the mutation activity in this site by the end of 2021, which persistently exhibits high signal ever since. For site V445, deLemus also has detected the mutation signal in this site since April 2022. The DMS study reported an escape capability of this site over mAbs COV2-2449.<br /></big>